Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Phase Ib/II Trial of LVGN6051 Combined With Anlotinib in the Treatment of Locally Advanced, Metastatic or Recurrent Refractory Soft Tissue Sarcoma

NCT05301764 is registered in ClinicalTrials.gov with Lyvgen Biopharma Holdings Limited as lead sponsor.

NCT NCT05301764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05301764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Phase Ib/II Trial of LVGN6051 Combined With Anlotinib in the Treatment of Locally Advanced, Metastatic or Recurrent Refractory Soft Tissue Sarcoma
Lead sponsor
Lyvgen Biopharma Holdings Limited
Phase
Phase 1/2
Overall status
Completed
Start date
May 25, 2022
Completion date
December 19, 2025
Enrollment
39 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

soft tissue sarcoma